During its July 2026 meeting, the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency recommended new safety information on desogestrel- and etonogestrel-containing contraceptives and Litfulo, a medicine to treat alopecia areata.Desogestrel- and etonogestrel-containing medicines: risk of meningioma and new measures to minimise the riskThe Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) agreed on a direct healthcare professional communication (DHPC) to inform healthcare professionals about a small increased risk of meningioma associated with current, prolonged use (more than one year) of desogestrel- or etonogestrel-containing contraceptive medicines. Although the risk is
FAMHP (Belgian Medicine Agency) · July 31, 2026
PRAC July 2026: new safety recommendations for desogestrel- and etonogestrel-containing contraceptives and Litfulo
Original title: PRAC July 2026: new safety recommendations for desogestrel- and etonogestrel-containing contraceptives and for Litfulo
EMA PRAC recommended direct healthcare professional communication on meningioma risk with desogestrel and etonogestrel contraceptives and new safety measures for Litfulo.
Published by FAMHP (Belgian Medicine Agency). HealthSignal links to the original document; the summary above is extracted from the source text.